Greg Findlay

Greg Findlay

GROUP LEADER (1ST 6)

Greg received his bachelor’s degree in biology from Carleton College in 2009, before working as a research technician with Drs. Anjana Rao and Tomas Kirchhausen at Harvard Medical School studying cellular signaling pathways of the immune system.

In 2012, Greg entered the Medical Scientist Training Program at the University of Washington in Seattle. He was awarded an ARCS Foundation scholarship in 2014, as well as a Ruth L. Kirschstein fellowship from the National Institutes of Health in 2016 to develop new genome editing methods to study mutations in cancer predisposition genes.

He completed his PhD in Genome Sciences in 2018 under the supervision of Dr. Jay Shendure. During this time, Greg led the development of several novel high-throughput genome editing methods. These included Saturation Genome Editing, which he employed to study thousands of mutations in BRCA1, ScanDel, a method for engineering large deletions in multiplex, and GESTALT, a CRISPR/Cas9-based lineage tracing technique. In 2019, Greg received the Innovation in Technology Award from the Western Association of Graduate Schools and Proquest for his PhD work.

Greg earned his MD from the University of Washington School of Medicine in 2020 before joining the Crick as a Group Leader shortly after.

Qualifications and history

2009
Immune Disease Institute at Harvard Medical School, Boston, USA
Research Technician
2012
University of Washington, Seattle, USA
Entered Medical Scientist Training Program
2016
National Institutes of Health, USA
warded Ruth Kirschstein Fellowship from the National Cancer Institute
2018
University of Washington, Seattle, USA
PhD, Genome Sciences
2020
University of Washington, Seattle, USA
MD, School of Medicine
2020
The Francis Crick Institute, London, UK
Group leader
Displaying 1 - 11 of 11
Last updated : 05 May 2021 02:22